

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/981,421	01/18/2002	John E. Sims	3086-A	6827
22932	7590 08/09/2004		EXAMINER	
IMMUNEX CORPORATION			JIANG, DONG	
LAW DEPAR	TMENT COURT WEST		ART UNIT	PAPER NUMBER
SEATTLE, W			1646	
			DATE MAILED: 08/09/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/981,421	SIMS ET AL.			
Office Action Summary	Examiner	Art Unit			
	Dong Jiang	1646			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period was period to reply within the set or extended period for reply will, by statute, any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed  /s will be considered timely.  In the mailing date of this communication.  ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on					
2a) This action is <b>FINAL</b> . 2b) ⊠ This	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
<ul> <li>4) ☐ Claim(s) 1-15 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdraw</li> <li>5) ☐ Claim(s) is/are allowed.</li> <li>6) ☐ Claim(s) is/are rejected.</li> <li>7) ☐ Claim(s) is/are objected to.</li> <li>8) ☐ Claim(s) 1-15 are subject to restriction and/or expression.</li> </ul>	wn from consideration.				
Application Papers					
9) The specification is objected to by the Examine	r.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicat rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage			
Attachment(s)					
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) ∭ Interview Summary Paper No(s)/Mail D				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date		Patent Application (PTO-152)			

Application/Control Number: 09/981,421

Art Unit: 1646

\*

## **DETAILED ACTION**

Currently, claims 1-15 are pending

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-3 and 9-15, drawn to a method of treatment by administering IL-18 antagonist, or IL-18 antagonist in combination with one or more compounds, wherein the IL-18 antagonist is soluble IL-18 receptor, classified in class 514, subclass 2.
- II. Claims 1, 4-7 and 9-15, drawn to a method of treatment by administering IL-18 antagonist, or IL-18 antagonist in combination with one or more compounds, wherein the IL-18 antagonist is an antibody, classified in class 424, subclass 133.1.
- III. Claims 1 and 8-15, drawn to a method of treatment by administering IL-18 antagonist, or IL-18 antagonist in combination with one or more compounds, wherein the IL-18 antagonist is soluble IL-18 binding protein, classified in class 514, subclass 2.

The inventions are distinct, each from the other because:

Although Inventions I-III are drawn to a method of treatment by administering IL-18 antagonist, or IL-18 antagonist in combination with one or more compounds, the IL-18 antagonists used in the groups are distinct as they are distinct chemical entities, thus burdensome and non-coextensive searches are required.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and/or recognized divergent subject matters, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/981,421

Art Unit: 1646

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/981,421

Art Unit: 1646

## Advisory Information

Any inquiry concerning this communication should be directed to Dong Jiang whose telephone number is 571-272-0872. The examiner can normally be reached on Monday - Friday from 9:30 AM to 7:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback, can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

LORRAINE SPECTOR PRIMARY EXAMINER

Dong Jiang, Ph.D. Patent Examiner AU1646 7/28/04